Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Measurement Frequency [Domain] Measurement Frequency [Domain] Anti-PD-1 (JEMPERLI/Dostarlimab) AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) [Member] AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Leasehold improvements Leasehold Improvements [Member] Net loss Net loss Net Income (Loss) Attributable to Parent Annual increase in number of shares available for issuance Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Entity Emerging Growth Company Entity Emerging Growth Company Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Short-term investments Debt Securities, Available-for-sale, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Accrued compensation and related expenses Employee-related Liabilities, Current City Area Code City Area Code Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Entity Address, Address Line One Entity Address, Address Line One Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Entity Address, Address Line Two Entity Address, Address Line Two Award expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Receivable from collaborative partners Increase (Decrease) in Contract with Customer, Asset Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Accrued research, development and manufacturing expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate US Treasury Securities US Treasury Securities [Member] Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Entity Filer Category Entity Filer Category Other long-term assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Proceeds from issuance of common stock, upon the exercise of stock options Proceeds from Stock Options Exercised Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Shares reserved for future award grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Phase 3 clinical trial initiation - first indication Phase 3 Clinical Trial Initiation - First Indication [Member] Phase 3 Clinical Trial Initiation - First Indication Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Issued and Outstanding: Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Equity Components [Axis] Equity Components [Axis] Forfeitures and cancellations (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Certificates of deposit Certificates of Deposit [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total current assets Assets, Current Document Fiscal Year Focus Document Fiscal Year Focus Total minimum payments required Lessee, Operating Lease, Liability, to be Paid Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Filing of the first BLA - second indication Filing of BLA - Second Indication [Member] Filing of BLA - Second Indication Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Entity File Number Entity File Number Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Security deposit Security Deposit Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Options to purchase common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense [Member] Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share GSK GlaxoSmithKline [Member] GlaxoSmithKline Weighted average grant date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Royalty percent on net sales Net Sales Royalty, Percent Net Sales Royalty, Percent Title of Individual [Domain] Title of Individual [Domain] Unrealized (loss) income on available for sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Award Type [Domain] Award Type [Domain] IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] Monthly base rate (usd per sqft) Rent Per Square Foot Rent Per Square Foot ASSETS Assets [Abstract] Available-for-sale Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Stock options exercisable, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Statement [Line Items] Statement [Line Items] Investments outstanding, maturity date range (in years) Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity Weighted-Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Maximum milestone payments per target Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at June 30, 2021 and December 31, 2020, respectively Preferred Stock, Value, Issued Long-term investments Debt Securities, Available-for-sale, Noncurrent Stock options issued and outstanding (in shares) Stock options outstanding, beginning balance (in shares) Stock options outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Revenue Recognition [Abstract] Revenue Recognition [Abstract] Entity Address, City or Town Entity Address, City or Town Summary of Non-cash Stock-based Compensation Expense Share-based Payment Arrangement, Cost by Plan [Table Text Block] Available-for-sale securities, debt securities Total Fair Value Debt Securities, Available-for-sale Accumulated Deficit Retained Earnings [Member] Counterparty Name [Domain] Counterparty Name [Domain] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Lease term Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Area of leased property (sqft) Area of Real Estate Property Entity Address, State or Province Entity Address, State or Province Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to) Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position Investments at fair value Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Leased assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Use of Estimates Use of Estimates, Policy [Policy Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Entity Interactive Data Current Entity Interactive Data Current Total assets Assets Director Stock options Director [Member] Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Phase 3 clinical trial initiation - second indication Phase 3 clinical Trial Initiation - Second Indication [Member] Phase 3 clinical Trial Initiation - Second Indication [Member] Basic (in dollars per share) Earnings Per Share, Basic Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Title of Individual [Axis] Title of Individual [Axis] Receivable related to issuance of common stock, upon exercise of stock options Receivables for Stock Options Exercised Receivables for Stock Options Exercised Payments on notes payable Repayments of Notes Payable Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] Lease termination term Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Celgene Corporation Bristol-Myers Squibb [Member] Bristol-Myers Squibb Document Type Document Type Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Entity Current Reporting Status Entity Current Reporting Status Measurement Frequency [Axis] Measurement Frequency [Axis] Milestone payments, contingent upon preclinical and clinical trial events (up to) Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Costs in Cash Flow Statement Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Increase in annual rent Annual Rent Increase, Percent Annual Rent Increase, Percent Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Stock-based compensation Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Amortization of right-of-use assets – operating Operating Lease, Right-of-Use Asset, Amortization Expense Receivable from collaborative partners Receivables, Net, Current 2017 Equity Incentive Plan 2017 Plan Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Plan Name [Axis] Plan Name [Axis] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accretion/amortization of investments, net Unrealized Gain (Loss) on Investments Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Document Transition Report Document Transition Report Weighted-average number of shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Capital shares reserved for future issuance, increase (in shares) Common Stock, Capital Shares Reserved For Future Issuance, Increase Common Stock, Capital Shares Reserved For Future Issuance, Increase Amendment Collaboration and Exclusive License Agreement [Member] Collaboration and Exclusive License Agreement Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Number of outstanding research and development targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Total liabilities and stockholders’ equity Liabilities and Equity Other Other Accrued Liabilities, Current Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Accounts payable Accounts Payable, Current Exercises (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Depreciation and amortization Depreciation, Depletion and Amortization Additional paid in capital Additional Paid in Capital Agency securities US Government Agencies Debt Securities [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Filing of the first MAA - first indication Filing of MMA - First Indication [Member] Filing of MMA - First Indication Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] 2017 Employee Stock Purchase Plan ESPP Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Operating expenses: Operating Expenses [Abstract] Anti-PD-1 (CC-90006) AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] Anti-LAG-3 (GSK40974386) AnaptysBio Generated Anti-LAG-3 (GSK40974386) [Member] AnaptysBio Generated Anti-LAG-3 (GSK40974386) Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Shares issued under employee stock plans Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Shares Subject to Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Forfeitures and cancellations (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Lease renewal term Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term Property and Equipment, net Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Income Statement Location [Domain] Income Statement Location [Domain] Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] 12 Months or Greater, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Trading Symbol Trading Symbol Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Current liabilities: Liabilities, Current [Abstract] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Restricted cash Restricted Cash and Cash Equivalents, Noncurrent AnaptysBio-generated Zejula AnaptysBio-generated Zejula [Member] AnaptysBio-generated Zejula General and administrative General and Administrative Expense Stockholders' Equity, Beginning Balance (in shares) Stockholders' Equity, Ending Balance (in shares) Shares, Outstanding Stock options exercisable, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Collaborative Research And Development Agreement Collaborative Arrangement [Member] Equity Incentive Plans Share-based Payment Arrangement [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Property and equipment, gross Property, Plant and Equipment, Gross Accounting Policies [Abstract] Accounting Policies [Abstract] Document Quarterly Report Document Quarterly Report Gross Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Weighted average remaining contractual term, options outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Number of reportable segments Number of Reportable Segments Accrued professional fees Accrued Professional Fees, Current Lease liability Total Operating Lease, Liability Stock options outstanding, beginning balance (in dollars per share) Stock options outstanding, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, $0.001 par value, 500,000 shares authorized, 27,433 shares and 27,356 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Total other income, net Nonoperating Income (Expense) Weighted average period remaining for amortization of unrecognized compensation cost (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Phase 1 clinical trial initiation Phase 1 Clinical Trial Initiation [Member] Phase 1 Clinical Trial Initiation [Member] First BLA approval - first indication First BLA Approval - dMMREC [Member] First BLA Approval - dMMREC Basis of Presentation Basis of Accounting, Policy [Policy Text Block] First MAA approval - first indication First MAA Approval - First Indication [Member] First MAA Approval - First Indication Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Upfront license fee received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Weighted average remaining contractual term, options exercisable (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to) Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Net loss per common share: Earnings Per Share, Basic and Diluted [Abstract] 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Document Fiscal Period Focus Document Fiscal Period Focus Summary of Weighted Average Assumptions used to Estimate Fair Value Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Restricted cash Restricted Cash, Current Counterparty Name [Axis] Counterparty Name [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Document Period End Date Document Period End Date Loss on disposal of tenant improvements and certain equipment Gain (Loss) on Disposition of Property Plant Equipment Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Entity Registrant Name Entity Registrant Name Allowance for credit losses Debt Securities, Available-for-sale, Allowance for Credit Loss Schedule of Unrealized Loss and Fair Values in a Loss Position Schedule of Unrealized Loss on Investments [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Current assets: Assets, Current [Abstract] Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Common stock, shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Interest income Interest Income (Expense), Nonoperating, Net Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name Unrealized losses on available-for-sale Debt Securities, Available-for-sale, Unrealized Loss Revenue Revenue from Contract with Customer [Policy Text Block] Shares issued under employee stock plans (in shares) Exercises (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Milestone payment earned Revenue Recognized, Milestone Method, Milestone Payment Earned Revenue Recognized, Milestone Method, Milestone Payment Earned Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Financial Instrument [Axis] Financial Instrument [Axis] Comprehensive income (loss), net Other Comprehensive Income (Loss), Net of Tax Accrued expenses Total accrued expenses Accrued Liabilities, Current Recurring Fair Value, Recurring [Member] Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Current Fiscal Year End Date Current Fiscal Year End Date Summary of Activity Related to Stock Option Awards Share-based Payment Arrangement, Option, Activity [Table Text Block] Office furniture and equipment Office Equipment [Member] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Anti-TIM-3 (GSK4069889A/Cobolimab) AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member] AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) Options to purchase common stock Share-based Payment Arrangement, Option [Member] Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Filing of the first BLA - first indication Filing of BLA - First Indication [Member] Filing of BLA - First Indication Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other income, net: Nonoperating Income (Expense) [Abstract] Milestones achieved, amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Name of Property [Axis] Name of Property [Axis] Class of Stock [Line Items] Class of Stock [Line Items] Less than 12 Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Common Stock Common Stock [Member] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loss from operations Operating Income (Loss) CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] General and administrative General and Administrative Expense [Member] Basis of Consolidation Consolidation, Policy [Policy Text Block] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Current portion of operating lease liability Operating Lease, Liability, Current Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current ESPP Employee Stock [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Stock-based compensation APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Lease Agreement 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Money market funds Money Market Funds [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Agreement term following first commercial sale or expiration of the last to expire patent (in years) Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Purchases of investments Payments to Acquire Debt Securities, Available-for-sale Number of milestones achieved during period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Mutual funds Mutual Fund [Member] Other income, net Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] Revenue recognition multiple deliverable arrangements upfront fee receivable Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Revenue Recognition Multiple Deliverable Arrangements Upfront Fees Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Schedule of Milestones Achieved Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Cover [Abstract] Cover [Abstract] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate intrinsic value, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders’ equity Stockholders' Equity, Beginning Balance Stockholders' Equity, Ending Balance Stockholders' Equity Attributable to Parent Less than 12 Months, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Name of Property [Domain] Name of Property [Domain] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Aggregate intrinsic value, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Description of the Business Nature of Operations [Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Operating lease cost Operating Lease, Cost Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] 12 Months or Greater, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] 10455 Building 10455 Pacific Center Court in San Diego, California [Member] 10455 Pacific Center Court in San Diego, California Initiated in vivo toxicology studies using good laboratory practices (GLPs) In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member] Collaboration Revenue [Member] Collaboration Revenue